---
title: Official Documents, Media Coverage and Research Articles
layout: page
description: 'Read about Evusheld in the media.'
image: assets/images/media.png
nav-menu: true
---
This page contains media coverage, research articles, preprints, medical opinion pieces, and policy documents. If we are missing items, please email them to [the maintainer](mailto:martin@eve.gd).

## Documents
These are documents issued or prepared by Evusheld for the UK or by charity partners with whom we work, here released in the interests of transparency.

* Evusheld for the UK. 2022. ‘[UK Government Privatises Covid Response and Forces Vulnerable Immunocompromised Patients to Pay for Covid Drugs](/assets/downloads/2022-10-20-Private-Provision-Press-Release.pdf)’. 20 October 2022.
* Evusheld for the UK. 2022. ‘[Submission to NICE consultation COVID-19 (prevention) - tixagevimab–cilgavimab ID6136](/assets/downloads/2022-10-09-NICE-Submission.pdf)’. 09 October 2022.
* Blood Cancer UK. 2022. ‘[Letter to the Secretary of State for Health](/assets/downloads/2022-10-04-Letter-to-Coffey.pdf)’. 04 October 2022.
* Evusheld for the UK. 2022. ‘[Response Letter to the New Secretary of State for Health](/assets/downloads/2022-09-16-Response-to-SoS.pdf)’. 20 September 2022.
* Evusheld for the UK. 2022. ‘[Joint Charity Letter to Secretary of State for Health](/assets/downloads/2022-08-23-Evusheld-Charity-Letter-to-Barclay.pdf)’. 23 August 2022.
* Evusheld for the UK. 2022. ‘[Response to DHSC Shelving Plans for Evusheld in Winter 2022](/assets/downloads/2022-08-12-DHSC-Response.pdf)’. 12 August 2022.
* Evusheld for the UK. 2022. ‘[Response to NICE Scoping Consultation: Tixagevimab–cilgavimab for preventing COVID-19, ID6136](/assets/downloads/NICE-Scoping.pdf)’. 11 August 2022.
* Evusheld for the UK. 2022. ‘[Department of Health Plans to Deny Lifesaving Treatment to Vulnerable Patients](/assets/downloads/2022-08-10-Press-Release.pdf)’. 10 August 2022.
* Evusheld for the UK. 2022. ‘[UK “Outlier” in Not Protecting 500,000+ Vulnerable Patients with New Lifesaving Drug. AstraZeneca Denies Government Claims of Further Testing](/assets/downloads/2022-06-21-Press-Release.pdf)’. 21 June 2022.

## Selected Media Coverage
These are articles in mainstream media/press releases about Evusheld in the UK, in reverse chronological order. It also includes statements from major UK charities on the drug.

* Harris, Siobhan. ‘[Medical Experts Ask for a Rethink on Evusheld](https://www.medscape.co.uk/viewarticle/medical-experts-ask-rethink-evusheld-2022a10021il)’. _Medscape UK_. Accessed 21 August 2022.
* Raphael, Therese, and Sam Fazeli. ‘[Britain Needs a Better Booster Strategy for Covid](https://www.washingtonpost.com/business/britain-needs-a-better-booster-strategy-for-covid/2022/08/19/99c04c2e-1f7c-11ed-9ce6-68253bd31864_story.html)’. _Washington Post_, 19 August 2022.
* Mahase, Elisabeth. ‘[Covid-19: UK Will Not Buy Evusheld Owing to “Insufficient Data” on Protection, Government Says](https://doi.org/10.1136/bmj.o2021)’. _BMJ_ 378 (15 August 2022): o2021.
* Walsh, Fergus. ‘[Covid: Evusheld Antibody Protection Ruled out for Most Vulnerable](https://www.bbc.com/news/health-62516896)’, _BBC News_, 12 August 2022, sec. Health.
* Davis, Nicola. ‘[UK Decision Not to Buy Covid Drug Evusheld Disappoints Charities](https://www.theguardian.com/world/2022/aug/12/uk-decision-not-to-buy-covid-drug-evusheld-disappoints-charities)’. _The Guardian_, 12 August 2022, sec. World news.
* Gallagher, Paul. ‘[Thousands of Vulnerable “in Limbo” as Government Rules out Buying Covid Protection Drug](https://inews.co.uk/news/health/evusheld-covid-uk-drug-prevent-high-risk-groups-vulnerable-people-1790926)’. _inews.co.uk_, 12 August 2022.
* Taylor, Phil. ‘[Dismay as UK “drags Its Heels” on AZ’s COVID Antibody Evusheld](https://pharmaphorum.com/news/dismay-as-uk-drags-its-heels-on-azs-covid-antibody-evusheld/)’. _Pharmaphorum_, 12 August 2022.
* AstraZeneca. ‘[Update to Evusheld Recommended Dosage Regimen for Pre-Exposure Prophylaxis of COVID-19](https://www.astrazeneca.com/media-centre/statements/2022/update-to-evusheld-recommended-dosage-regimen-for-pre-exposure-prophylaxis-of-covid-19.html)’, 14 July 2022.
* Sarcoidosis UK. ‘[SarcoidosisUK Evusheld Statement](https://www.sarcoidosisuk.org/information-hub/evusheld/)’. _SarcoidosisUK_, 10 July 2022.
* Cardiomyopathy UK. ‘[A Statement on Evusheld](https://www.cardiomyopathy.org/news-blogs/latest-news/evusheld)’. _Cardiomyopathy UK_, 8 July 2021.
* Davies, Joe. ‘[Calls for UK to Stock up on Covid Drug That Slashes Illness by 80%](https://www.msn.com/en-gb/health/medical/calls-for-uk-to-stock-up-on-covid-drug-that-slashes-illness-by-80percent/ar-AAZj9Mf)’. _Daily Mail_, 7 July 2022.
* Lay, Kat. ‘[Calls Grow for Government to Order Covid Drug to Boost Protection for Vulnerable](https://www.thetimes.co.uk/article/calls-grow-for-government-to-order-covid-drug-to-boost-protection-for-vulnerable-h6x7gq229)’. _The Times_, 6 July 2022, sec. news.
* Lennard, Lee. ‘[Consultation for an Independent Clinical Consensus Statement for Protective Measures for VGP](/assets/downloads/2022-07-05-APPG.pdf)’. All-Party Parliamentary Group on Vulnerable Groups to Pandemics, 5 July 2022.
* Ennals, Ethan. ‘[Will Covid Drug Evusheld Be Offered to Brits Who Don’t Respond to Jab?](https://www.dailymail.co.uk/health/article-10976341/Will-Covid-drug-Evusheld-offered-vulnerable-Britons-dont-respond-vaccine.html)’. _Mail Online_, 2 July 2022.
* Mullard, Asher. ‘[COVID Antibody Drugs Have Saved Lives — so Why Aren’t They More Popular?](https://doi.org/10.1038/d41586-022-01735-7)’ _Nature_ 606, no. 7916 (29 June 2022): 854–56.
* Sharp, Christopher. ‘[Blood Cancer UK Says Government “Needs to Do More” amid Battle for Evusheld](https://www.express.co.uk/life-style/health/1629554/blood-cancer-uk-treatment-evusheld-covid)’. _Express.co.uk_, 26 June 2022.
* Shapiro, Lindsey. 2022. ‘[Evusheld Boosts Antibodies Against COVID-19 in Vaccinated MS Patients](https://multiplesclerosisnewstoday.com/news-posts/2022/06/10/evusheld-boosts-antibodies-against-covid-19-vaccinated-ms-patients/)’. _Multiple Sclerosis News Today_ (blog). 10 June 2022.
* ‘[Evusheld Significantly Prevented COVID-19 Disease Progression or Death in Tackle Phase III Treatment Trial](https://www.zawya.com/en/press-release/companies-news/evusheld-significantly-prevented-covid-19-disease-progression-or-death-in-tackle-phase-iii-treatment-trial-appg120c)’. 2022. _Zawya_. 10 June 2022.
* ‘[AstraZeneca’s Evusheld Prevents Disease Progression in Phase III Covid-19 Trial](https://www.clinicaltrialsarena.com/news/astrazeneca-evusheld-covid-trial-2/)’. 2022. _Clinical Trials Arena_ (blog). 9 June 2022.
* AstraZeneca. 2022. ‘[Evusheld Significantly Prevented COVID-19 Disease Progression or Death in TACKLE Phase III Treatment Trial](https://www.astrazeneca.com/media-centre/press-releases/2022/evusheld-significantly-prevented-covid-19-disease-progression-or-death-in-tackle-phase-iii-treatment-trial.html)’. 8 June 2022.
* Chudleigh, Hannah. 2022. ‘[AstraZeneca’s Evusheld Successfully Prevents Progression to Severe COVID-19](https://www.biospace.com/article/astrazeneca-s-evusheld-successfully-prevents-progression-to-severe-covid-19-/)’. _BioSpace_. 8 June 2022.
* Kahn, Rachel. 2022. ‘[Evusheld – Does It Work against Omicron?](https://bloodcancer.org.uk/news/evusheld-does-it-work-against-omicron/)’ _Blood Cancer UK_. 6 June 2022.
* Sharp, Christopher. 2022. ‘[Covid: Why the Threat of the Virus Still Haunts Those Who Are Immunosuppressed](https://www.express.co.uk/life-style/health/1615894/covid-kidney-disease-immunosuppressed-exclusive/amp)’. Express, 29 May 2022.
* AstraZeneca. 2022. ‘[Evusheld Long-Acting Antibody Combination Retains Neutralising Activity against Omicron Variants BA.4 and BA.5, According to New Study from University of Oxford](https://www.astrazeneca.com/media-centre/medical-releases/evusheld-long-acting-antibody-combination-retains-neutralising-activity-omicron-variants-ba4-ba5-according-new-study-university-oxford.html)’. 25 May 2022.
* Barnes, Oliver. 2022. ‘[UK Accused of Leaving Covid Immunocompromised “out to Dry”](https://www.ft.com/content/fe03bc3b-a381-462d-b373-87dabde0a9ab)’. _Financial Times_, 4 May 2022.
* Kollewe, Julia. 2022. ‘[AstraZeneca Boss Calls for UK to Provide New Covid-19 Medicine to the Vulnerable](https://www.theguardian.com/business/2022/apr/29/evusheld-covid-19-medicine-astrazeneca-immunosuppressed-vulnerable-uk)’. _The Guardian_, 29 April 2022, sec. Business.
* Ennals, Ethan. 2022. ‘[Covid 19: Vulnerable Patients Denied £800 Anti-Viral Jab Unless They Go Private](https://www.dailymail.co.uk/health/article-10746187/Covid-19-Vulnerable-patients-denied-800-anti-viral-jab-unless-private.html)’. Daily Mail. 23 April 2022.
* AstraZeneca. 2022. ‘[Evusheld Long-Acting Antibody Combination Retains Neutralising Activity against Omicron Variants Including BA.2 in New Independent Studies](https://www.astrazeneca.com/media-centre/medical-releases/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variants-including-ba2-in-new-independent-studies.html)’. 21 March 2022.
* ‘[Evusheld Approved to Prevent COVID-19 in People Whose Immune Response Is Poor](https://www.gov.uk/government/news/evusheld-approved-to-prevent-covid-19-in-people-whose-immune-response-is-poor)’. 2022. GOV.UK. 17 March 2022.
* AstraZeneca. 2022. ‘[AstraZeneca’s Antibody Combination, Evusheld (Tixagevimab Co-Packaged with Cilgavimab) Authorised for Use in Great Britain for Pre-Exposure Prophylaxis (Prevention) of COVID-19](https://www.astrazeneca.com/media-centre/press-releases/2022/astrazenecas-antibody-combination-evusheld-authorised-for-use-in-great-britain-for-pre-exposure-prophylaxis-prevention-of-covid-19.html)’. 17 March 2022.
* ‘[Individuals with Immunodeficiency at High Risk of Mortality Following SARS-CoV-2 Infection](https://www.birmingham.ac.uk/news/latest/2022/01/covid-immunodeficiency-death-risk-infection.aspx)’. 2022. University of Birmingham. 31 January 2022.


## Research Articles, Preprints, Medical Opinion Pieces, and Policy Documents
These are formal research studies into the efficacy and dosage of Evusheld. These are arranged by alphabetical order of first author. We list here all articles (attempting a comprehensive literature review) rather than merely those with positive findings.

Articles marked [PREPRINT] have not necessarily been subject to [peer review](https://en.wikipedia.org/wiki/Peer_review).

* ‘[COVID-19 Update: Hypersensitivity Reactions with Tixagevimab/Cilgavimab (Evusheld)](https://secure.medicalletter.org/TML-article-1654d)’. The Medical Letter on Drugs and Therapeutics 64, no. 1654 (11 July 2022): 112.
* ‘[COVID-19 Update: Dosing Interval for Tixagevimab/Cilgavimab (Evusheld)](https://secure.medicalletter.org/TML-article-1656b)’. _The Medical Letter on Drugs and Therapeutics_, 8 August 2022.
* ACTIV-3–Therapeutics for Inpatients with COVID-19 (TICO) Study Group. ‘[Tixagevimab–Cilgavimab for Treatment of Patients Hospitalised with COVID-19: A Randomised, Double-Blind, Phase 3 Trial](https://doi.org/10.1016/S2213-2600(22)00215-6)’. _The Lancet Respiratory Medicine_, 8 July 2022.
* Aggarwal, Anupriya, Anouschka Akerman, Vanessa Milogiannakis, Mariana Ruiz Silva, Gregory Walker, Alberto Ospina Stella, Andrea Kindinger, et al. ‘[SARS-CoV-2 Omicron BA.5: Evolving Tropism and Evasion of Potent Humoral Responses and Resistance to Clinical Immunotherapeutics Relative to Viral Variants of Concern](https://doi.org/10.1016/j.ebiom.2022.104270)’. _EBioMedicine_ 84 (18 September 2022): 104270.
* Aisenberg, Gabriel M. ‘[In Persons at Risk for Poor Vaccination Response or COVID-19 Exposure, Tixagevimab + Cilgavimab Reduced COVID-19]( https://doi.org/10.7326/J22-0056)’. _Annals of Internal Medicine_ 175, no. 8 (16 August 2022): JC92.
* Akinosoglou, Karolina, Emmanouil-Angelos Rigopoulos, Georgia Kaiafa, Stylianos Daios, Eleni Karlafti, Eleftheria Ztriva, Georgios Polychronopoulos, Charalambos Gogos, and Christos Savopoulos. ‘[Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience](https://doi.org/10.3390/v15010118)’. _Viruses_ 15, no. 1 (30 December 2022): 118.
* Alejo, Jennifer L., Jake D. Kim, Teresa Py Chiang, Robin K. Avery, Andrew H. Karaba, Alexa Jefferis, Daniel S. Warren, et al. ‘[Patient-Reported Outcomes after Tixagevimab and Cilgavimab Pre-Exposure Prophylaxis among Solid Organ Transplant Recipients: Safety, Effectiveness, and Perceptions of Risk](https://doi.org/10.1111/ctr.14913)’. _Clinical Transplantation_, 18 January 2023, e14913.
* Alhumaid, Saad, Abbas Al Mutair, Jalal Alali, Nourah Al Dossary, Sami Hussain Albattat, Sarah Mahmoud Al HajjiMohammed, Fatimah Saad Almuaiweed, et al. ‘[Efficacy and Safety of Tixagevimab/Cilgavimab to Prevent COVID-19 (Pre-Exposure Prophylaxis): A Systematic Review and Meta-Analysis](https://doi.org/10.3390/diseases10040118)’. _Diseases_ 10, no. 4 (1 December 2022): 118.
* Al-Obaidi, Mohanad M., Ahmet B. Gungor, Sandra E. Kurtin, Ann E. Mathias, Bekir Tanriover, and Tirdad T. Zangeneh. ‘[The Prevention of COVID-19 in High-Risk Patients Using Tixagevimab–Cilgavimab (Evusheld): Real-World Experience at a Large Academic Center](https://doi.org/10.1016/j.amjmed.2022.08.019)’. The American Journal of Medicine, 28 September 2022.
* Anmar, Al-Taie. ‘[Tixagevimab and Cilgavimab: Can We See More Recommendations for Monoclonal Antibodies Beyond COVID-19 Vaccination](https://doi.org/10.1017/dmp.2022.150)’. _Disaster Medicine and Public Health Preparedness_, 8 June 2022, 1–2.
* Atluri, Kavya, Iris Aimlin, and Shitij Arora. ‘[Current Effective Therapeutics in Management of COVID-19](https://doi.org/10.3390/jcm11133838)’. Journal of Clinical Medicine 11, no. 13 (1 July 2022): 3838.
* Aqeel, Faten, and Duvuru Geetha. ‘Tixagevimab and Cilgavimab (Evusheld) in Rituximab-Treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients’. [Kidney International Reports](https://doi.org/10.1016/j.ekir.2022.08.019), 27 August 2022.
* Baloda, Vandana, Erin K. McCreary, Breana K. Goscicki, Michael R. Shurin, and Sarah E. Wheeler. ‘[Tixagevimab Plus Cilgavimab Does Not Affect the Interpretation of Electrophoretic and Free Light Chain Assays](https://doi.org/10.1093/ajcp/aqac137)’. _American Journal of Clinical Pathology_, 5 December 2022, aqac137.
* Bender Ignacio, Rachel A., David A. Wohl, Rosalin Arends, Venkatesh Pilla Reddy, Ying Mu, Arzhang Cyrus Javan, Michael D. Hughes, et al. ‘[Comparative Pharmacokinetics of Tixagevimab/Cilgavimab (AZD7442) Administered Intravenously Versus Intramuscularly in Symptomatic SARS-CoV-2 Infection](https://doi.org/10.1002/cpt.2706)’. _Clinical Pharmacology and Therapeutics_, 7 July 2022.
* Benotmane, Ilies, Aurélie Velay, Gabriela Gautier Vargas, Jérôme Olagne, Olivier Thaunat, Samira Fafi-Kremer, and Sophie Caillard. ‘[Pre-Exposure Prophylaxis with 300 Mg Evusheld Elicits Limited Neutralizing Activity against the Omicron Variant](https://doi.org/10.1016/j.kint.2022.05.008)’. _Kidney International_, 24 May 2022, S0085-2538(22)00383-0.
* Benotmane, Ilies, Aurélie Velay, Gabriela Gautier Vargas, Jérôme Olagne, Augustin Obrecht, Noëlle Cognard, Francoise Heibel, et al. ‘[Breakthrough COVID-19 Cases despite Prophylaxis with 150 Mg of Tixagevimab and 150 Mg of Cilgavimab in Kidney Transplant Recipients](https://doi.org/10.1111/ajt.17121)’. _American Journal of Transplantation_. Accessed 23 June 2022.
* Benotmane, Ilies, Aurélie Velay, Gabriela Gautier Vargas, Jérôme Olagne, Noëlle Cognard, Francoise Heibel, Laura Braun-Parvez, et al. ‘[A Rapid Decline in the Anti-Receptor Binding Domain of the SARS-CoV-2 Spike Protein IgG Titer in Kidney Transplant Recipients after Tixagevimab-Cilgavimab Administration](https://doi.org/10.1016/j.kint.2022.07.022)’. _Kidney International_ (13 August 2022).
* Bertrand, Dominique, Charlotte Laurent, Veronique Lemée, Ludivine Lebourg, Mélanie Hanoy, Frank Le Roy, Dorian Nezam, et al. ‘[Efficacy of Anti-SARS-CoV-2 Monoclonal Antibody Prophylaxis and Vaccination on the Omicron Variant of COVID-19 in Kidney Transplant Recipients](https://doi.org/10.1016/j.kint.2022.05.007)’. _Kidney International_ 102, no. 2 (August 2022): 440–42.
* Birabaharan, Morgan, Eddie Hill, Maedha Begur, David C. Kaelber, Thomas Cs Martin, and Sanjay R. Mehta. ‘[Cardiovascular Outcomes after Tixagevimab and Cilgavimab Use for Pre-Exposure Prophylaxis against COVID-19: A Population-Based Propensity-Matched Cohort Study](https://doi.org/10.1093/cid/ciac894)’. _Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America_, 16 November 2022, ciac894.
* Boschi, Céline, Philippe Colson, Audrey Bancod, Valérie Moal, and Bernard La Scola. ‘[Omicron Variant Escapes Therapeutic Monoclonal Antibodies (MAbs) Including Recently Released Evusheld®, Contrary to 8 Prior Main Variant of Concern (VOC)](https://doi.org/10.1093/cid/ciac143)’. _Clinical Infectious Diseases_, 16 February 2022, ciac143.
* Brady, Drugan K., Aashi R. Gurijala, Liyu Huang, Ali A. Hussain, Audrey L. Lingan, Olivia G. Pembridge, Brina A. Ratangee, Tristan T. Sealy, Kyle T. Vallone, and Thomas P. Clements. ‘[A Guide to COVID-19 Antiviral Therapeutics: A Summary and Perspective of the Antiviral Weapons Against SARS-CoV-2 Infection](https://doi.org/10.1111/febs.16662)’. _The FEBS Journal_, 20 October 2022.
* Brady, Tyler, Tianhui Zhang, Kevin M. Tuffy, Nantaporn Haskins, Qun Du, Jia Lin, Gilad Kaplan, et al. ‘[Qualification of a Biolayer Interferometry Assay to Support AZD7442 Resistance Monitoring](https://doi.org/10.1128/spectrum.01034-22)’. _Microbiology Spectrum_ 10, no. 5 (22 August 2022): e01034-22.
* Bruel, Timothée, Jérôme Hadjadj, Piet Maes, Delphine Planas, Aymeric Seve, Isabelle Staropoli, Florence Guivel-Benhassine, et al. ‘[Serum Neutralization of SARS-CoV-2 Omicron Sublineages BA.1 and BA.2 in Patients Receiving Monoclonal Antibodies](https://doi.org/10.1038/s41591-022-01792-5)’. _Nature Medicine_ 28, no. 6 (June 2022): 1297–1302.
* Bruel, Timothée, Karl Stéfic, Yann Nguyen, Donatella Toniutti, Isabelle Staropoli, Françoise Porrot, Florence Guivel-Benhassine, et al. ‘[Longitudinal Analysis of Serum Neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in Patients Receiving Monoclonal Antibodies](https://doi.org/10.1016/j.xcrm.2022.100850)’. _Cell Reports_. Medicine, 17 November 2022, 100850.
* [PREPRINT] Bruel, Timothée, Karl Stéfic, Yann Nguyen, Donatella Toniutti, Isabelle Staropoli, Françoise Porrot, Florence Guivel-Benhassine, et al. ‘[Longitudinal Analysis of Serum Neutralization of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 in Patients Receiving Monoclonal Antibodies](https://doi.org/10.1101/2022.08.12.22278699)’. _medRxiv_, 13 August 2022.
* Calabrese, Cassandra, Elizabeth Kirchner, Alexandra Villa-Forte, Rula A. Hajj-Ali, Brandon P. Moss, James P. Fernandez, and Leonard Calabrese. ‘[Early Experience with Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis in Patients with Immune-Mediated Inflammatory Disease Undergoing B Cell Depleting Therapy and Those with Inborn Errors of Humoral Immunity](https://doi.org/10.1136/rmdopen-2022-002557)’. _RMD Open_ 8, no. 2 (1 September 2022): e002557.
* Cao, Yunlong, Weiliang Song, Lei Wang, Pan Liu, Can Yue, Fanchong Jian, Yuanling Yu, et al. ‘[Characterization of the Enhanced Infectivity and Antibody Evasion of Omicron BA.2.75](https://doi.org/10.1016/j.chom.2022.09.018)’. _Cell Host & Microbe_, 4 October 2022, S1931-3128(22)00511-X.
* Case, James Brett, Samantha Mackin, John M. Errico, Zhenlu Chong, Emily A. Madden, Bradley Whitener, Barbara Guarino, et al. ‘[Resilience of S309 and AZD7442 Monoclonal Antibody Treatments against Infection by SARS-CoV-2 Omicron Lineage Strains](https://doi.org/10.1038/s41467-022-31615-7)’. _Nature Communications_ 13, no. 1 (2 July 2022): 3824.
* Chavda, Vivek P., Riddhi Prajapati, Disha Lathigara, Bhumi Nagar, Jay Kukadiya, Elrashdy M. Redwan, Vladimir N. Uversky, Mukesh N. Kher, and Rajvi Patel. ‘[Therapeutic Monoclonal Antibodies for COVID-19 Management: An Update](https://doi.org/10.1080/14712598.2022.2078160)’. _Expert Opinion on Biological Therapy_ 22, no. 6 (June 2022): 763–80.
* Chollet, Vincent, Oriol Manuel, and Serge De Vallière. ‘[COVID-19, how to treat the disease during Fall 2022?](https://doi.org/10.53738/REVMED.2022.18.802.2077)’. Revue Medicale Suisse 18, no. 802 (2 November 2022): 2077–81.
* Conte, William L., and Lilian Golzarri-Arroyo. 2022. ‘[Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-CoV-2 in Patients with Multiple Sclerosis on b-Cell Depleters](https://doi.org/10.1016/j.msard.2022.103905)’. _Multiple Sclerosis and Related Disorders_ 63 (July): 103905.
* Convertino, Irma, Sara Ferraro, Emiliano Cappello, Giulia Valdiserra, Marco Bonaso, and Marco Tuccori. ‘[Tixagevimab + Cilgavimab against SARS-CoV-2: The Preclinical and Clinical Development and Real-World Evidence](https://doi.org/10.1080/17460441.2023.2170348)’. _Expert Opinion on Drug Discovery_, 17 January 2023.
* Das, Nabarun Chandra, Pritha Chakraborty, Jagadeesh Bayry, and Suprabhat Mukherjee. ‘[In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike Protein](https://doi.org/10.3389/fimmu.2021.782506)’. _Frontiers in Immunology_ 12 (2021): 782506.
* Degirmenci, Huseyin Berk, Jinseo Oh, Alison M. Bays, Jenna L. Thomason, and Jean W. Liew. ‘[Public Interest in COVID-19 Therapeutics for High-Risk Populations During the Omicron Era: A Google Trends Analysis](https://doi.org/10.7759/cureus.32684)’. _Cureus_ 14, no. 12 (December 2022): e32684.
* [PREPRINT] Desautels, Thomas A., Kathryn T. Arrildt, Adam T. Zemla, Edmond Y. Lau, Fangqiang Zhu, Dante Ricci, Stephanie Cronin, et al. ‘[Computationally Restoring the Potency of a Clinical Antibody against SARS-CoV-2 Omicron Subvariants](https://doi.org/10.1101/2022.10.21.513237)’. _BioRxiv: The Preprint Server for Biology_, 24 October 2022, 2022.10.21.513237.
* Dippel, Andrew, Austin Gallegos, Vineela Aleti, Arnita Barnes, Xiaoru Chen, Elizabeth Christian, Jared Delmar, et al. ‘[Developability Profiling of a Panel of Fc Engineered SARS-CoV-2 Neutralizing Antibodies](https://doi.org/10.1080/19420862.2022.2152526)’. _MAbs_ 15, no. 1 (2023): 2152526.
* Dong, Jinhui, Seth J. Zost, Allison J. Greaney, Tyler N. Starr, Adam S. Dingens, Elaine C. Chen, Rita E. Chen, et al. ‘[Genetic and Structural Basis for SARS-CoV-2 Variant Neutralization by a Two-Antibody Cocktail](https://doi.org/10.1038/s41564-021-00972-2)’. _Nature Microbiology_ 6, no. 10 (October 2021): 1233–44.
* Fitzsimmons, William E. ‘[COVID-19 Vaccine Associated Transverse Myelitis-Evusheld as an Option When Vaccination Is Not Recommended Due to Severe Adverse Events](https://doi.org/10.1080/21645515.2022.2068338)’. Human Vaccines & Immunotherapeutics, 5 May 2022, 1–2.
* Focosi, Daniele, and Arturo Casadevall. ‘[A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment](https://doi.org/10.3390/v14091999)’. _Viruses_ 14, no. 9 (9 September 2022): 1999.
* Focosi, Daniele, Fabrizio Maggi, Shmuel Shoham, and Arturo Casadevall. ‘[Discriminating Endogenous Vaccine-Elicited Anti-Spike Antibody Responses from Exogenous Anti-Spike Monoclonal Antibodies: The Case of Evusheld](https://doi.org/10.1002/jmv.28277)’. _Journal of Medical Virology_, 3 November 2022, e28277.
* [PREPRINT] Focosi, Daniele, Rodrigo Quiroga, Scott A. McConnell, Marc C. Johnson, and Arturo Casadevall. ‘[Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup That Causes New COVID-19 Waves](https://doi.org/10.1101/2022.12.05.518843)’. _bioRxiv_, 5 December 2022.
* Forte-Soto, Pablo, Muna Albayaty, Dennis Brooks, Rosalinda H. Arends, John Tillinghast, Anastasia A. Aksyuk, Jerome Bouquet, et al. ‘[Safety, Tolerability and Pharmacokinetics of Half-Life Extended SARS-CoV-2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab/Cilgavimab) in Healthy Adults](https://doi.org/10.1093/infdis/jiad014)’. _The Journal of Infectious Diseases_, 23 January 2023, jiad014.
* Hu, Ye-Fan, Jing-Chu Hu, Hin Chu, Thomas Yau, Bao-Zhong Zhang, and Jian-Dong Huang. ‘[In-Silico Analysis of Monoclonal Antibodies against SARS-CoV-2 Omicron](https://doi.org/10.3390/v14020390)’. _Viruses_ 14, no. 2 (14 February 2022): 390.
* Iacobucci, Gareth. ‘[Evusheld: Government Is Urged to Expedite Covid Antibody Treatment for Vulnerable Patients](https://doi.org/10.1136/bmj.o2431)’. _BMJ_ 379 (2022): o2431.
* Iacobucci, Gareth. ‘[Covid-19: Evusheld Protects the Most Vulnerable Patients, Analysis Shows](https://doi.org/10.1136/bmj.o2690)’. _BMJ_ 379 (8 November 2022): o2690.
* Jondreville, Ludovic, Maud D’Aveni, Hélène Labussière-Wallet, Amandine Le Bourgeois, Alban Villate, Ana Berceanu, Silvia-Maria Bezsera, et al. ‘[Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab (AZD7442) Prevents Severe SARS-CoV-2 Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation during the Omicron Wave: A Multicentric Retrospective Study of SFGM-TC](https://doi.org/10.1186/s13045-022-01387-0)’. _Journal of Hematology & Oncology_ 15, no. 1 (28 November 2022): 169.
* Jugler, Collin, Haiyan Sun, Katherine Nguyen, Roman Palt, Mitchell Felder, Herta Steinkellner, and Qiang Chen. ‘[A Novel Plant-Made Monoclonal Antibody Enhances the Synergetic Potency of an Antibody Cocktail against the SARS-CoV-2 Omicron Variant](https://doi.org/10.1111/pbi.13970)’. _Plant Biotechnology Journal_, 20 November 2022.
* [PREPRINT] Jurdi, Ayman Al, Leela Morena, Mariesa Cote, Emily Bethea, Jamil Azzi, and Leonardo V. Riella. 2022. ‘[Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis Is Associated with Lower Breakthrough Infection Risk in Vaccinated Solid Organ Transplant Recipients during the Omicron Wave](https://doi.org/10.1101/2022.05.17.22274980)’. _medRxiv_.
* Kaminski, Hannah, Mickael Gigan, Agathe Vermorel, Manon Charrier, Laura Guirle, Frederic Jambon, Arthur Lacapère, et al. ‘[Covid-19 Morbidity Decreases with Tixagevimab/Cilgavimab Preexposure Prophylaxis in Kidney Transplant Recipients Non/Low Vaccine Responders](https://doi.org/10.1016/j.kint.2022.07.008)’. _Kidney International_, 20 July 2022, S0085-2538(22)00550-6.
* Kaplon, Hélène, Silvia Crescioli, Alicia Chenoweth, Jyothsna Visweswaraiah, and Janice M. Reichert. ‘[Antibodies to Watch in 2023](https://doi.org/10.1080/19420862.2022.2153410)’. _MAbs_ 15, no. 1 (2023): 2153410.
* [PREPRINT] Karaba, Andrew H., Jake D. Kim, Teresa P.-Y. Chiang, Jennifer L. Alejo, Aura T. Abedon, Jonathan Mitchell, Amy Chang, et al. ‘[Omicron BA.1 and BA.2 Neutralizing Activity Following Pre-Exposure Prophylaxis with Tixagevimab plus Cilgavimab in Vaccinated Solid Organ Transplant Recipients](https://doi.org/10.1101/2022.05.24.22275467)’. _MedRxiv: The Preprint Server for Health Sciences_, 26 May 2022, 2022.05.24.22275467.
* Keam, Susan J. ‘[Tixagevimab + Cilgavimab: First Approval](https://doi.org/10.1007/s40265-022-01731-1)’. _Drugs_, 21 June 2022.
* Kertes, Jennifer, Shirley Shapiro Ben David, Noya Engel-Zohar, Keren Rosen, Beatriz Hemo, Avner Kantor, Limor Adler, Naama Shamir Stein, Miri Mizrahi Reuveni, and Arnon Shahar. ‘[Association between AZD7442 (Tixagevimab-Cilgavimab) Administration and SARS-CoV-2 Infection, Hospitalization and Mortality](https://doi.org/10.1093/cid/ciac625)’. _Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America_, 29 July 2022, ciac625.
* Konyak, Beyau M., Mohan Sharma, Shabnam Kharia, Ramendra Pati Pandey, and Chung-Ming Chang. ‘[A Systematic Review on the Emergence of Omicron Variant and Recent Advancement in Therapies](https://doi.org/10.3390/vaccines10091468)’. _Vaccines_ 10, no. 9 (5 September 2022): 1468.
* Kotton, Camille N. ‘[Belt and Suspenders: Vaccines and Tixagevimab/Cilgavimab for Prevention of COVID-19 in Immunocompromised Patients](https://doi.org/10.7326/M22-1026)’. _Annals of Internal Medicine_, 12 April 2022.
* Lamballerie, Xavier de, Guillaume Martin-Blondel, Axelle Dupont, Jacques Izopet, France Mentré, Nassim Kamar, Brigitte Autran, et al. ‘[Low Serum Neutralization of Omicron Variants a Month after AZD7442 Prophylaxis Initiation](https://doi.org/10.1016/j.jinf.2022.10.006)’. _The Journal of Infection_, 8 October 2022, S0163-4453(22)00565-5.
* Lee, Lennard, Keeley Bernhardt, Antonio Pagliuca, and Alex Richter. ‘[Abandoning the Winter 2022 Protection for the Immunocompromised - a Highly Irregular, Uncomfortable Decision for a Vulnerable Group That We Are Likely to Regret](https://www.bmj.com/content/378/bmj.o2021/rr).’ _BMJ_, no. 2022;378:o2021 (22 August 2022).
* Levin, Myron J., Andrew Ustianowski, Stéphane De Wit, Odile Launay, Miles Avila, Alison Templeton, Yuan Yuan, et al. ‘[Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19](https://doi.org/10.1056/NEJMoa2116620)’. The _New England Journal of Medicine_ 386, no. 23 (9 June 2022): 2188–2200.
* Levin, Myron J., Andrew Ustianowski, Steven Thomas, Alison Templeton, Yuan Yuan, Seth Seegobin, Catherine F. Houlihan, et al. ‘[AZD7442 (Tixagevimab/Cilgavimab) for Post-Exposure Prophylaxis of Symptomatic COVID-19](https://doi.org/10.1093/cid/ciac899)’. _Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America_, 22 November 2022, ciac899.
* Loo, Yueh-Ming, Patrick M. McTamney, Rosalinda H. Arends, Michael E. Abram, Anastasia A. Aksyuk, Seme Diallo, Daniel J. Flores, et al. ‘[The SARS-CoV-2 Monoclonal Antibody Combination, AZD7442, Is Protective in Nonhuman Primates and Has an Extended Half-Life in Humans](https://doi.org/10.1126/scitranslmed.abl8124)’. _Science Translational Medicine_ 14, no. 635 (9 March 2022): eabl8124.
* Mahase, Elisabeth. ‘[Covid-19: AstraZeneca Says Its Antibody Drug AZD7442 Is Effective for Preventing and Reducing Severe Illness](https://doi.org/10.1136/bmj.n2860)’. _BMJ (Clinical Research Ed.)_ 375 (19 November 2021): n2860.
* Maselkar, Sheetal, Alexandre Kiazand, Alison Templeton, Hugh Montgomery, and Mark T. Esser. ‘[Cardiac and Vascular Serious Adverse Events Following Tixagevimab-Cilgavimab - Author’s Reply](https://doi.org/10.1016/S2213-2600(22)00450-7)’. The Lancet. Respiratory Medicine, 12 December 2022, S2213-2600(22)00450-7.
* Mu, Ruipeng, Yue Huang, Jerome Bouquet, Jiaqi Yuan, Robert J. Kubiak, Eric Ma, Sami Naser, et al. ‘[Multiplex Hybrid Antigen-Capture LC-MRM Quantification in Sera and Nasal Lining Fluid of AZD7442, a SARS-CoV-2-Targeting Antibody Combination](https://doi.org/10.1021/acs.analchem.2c01320)’. _Analytical Chemistry_, 21 October 2022.
* Mu, Ruipeng, Yue Huang, Jerome Bouquet, Jiaqi Yuan, Robert J. Kubiak, Eric Ma, Sami Naser, et al. ‘[Multiplex Hybrid Antigen-Capture LC-MRM Quantification in Sera and Nasal Lining Fluid of AZD7442, a SARS-CoV-2-Targeting Antibody Combination](https://doi.org/10.1021/acs.analchem.2c01320)’. _Analytical Chemistry_ 94, no. 43 (1 November 2022): 14835–45.
* Najjar-Debbiny, Ronza, Naomi Gronich, Gabriel Weber, Nili Stein, and Walid Saliba. ‘[Effectiveness of Evusheld in Immunocompromised Patients: Propensity Score-Matched Analysis](https://doi.org/10.1093/cid/ciac855)’. _Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America_, 31 October 2022, ciac855.
* NHS England RAPID-C19. 2022. ‘[Defining the Highest-Risk Clinical Subgroups upon Community Infection with SARS-CoV-2 When Considering the Use of Neutralising Monoclonal Antibodies (NMABs) and Antiviral Drugs: Independent Advisory Group Report](https://www.gov.uk/government/publications/higher-risk-patients-eligible-for-covid-19-treatments-independent-advisory-group-report/defining-the-highest-risk-clinical-subgroups-upon-community-infection-with-sars-cov-2-when-considering-the-use-of-neutralising-monoclonal-antibodies)’. _GOV.UK_. 30 May 2022.
* Nguyen, Yann, Adrien Flahault, Nathalie Chavarot, Cléa Melenotte, Morgane Cheminant, Paul Deschamps, Nicolas Carlier, et al. ‘[Pre-Exposure Prophylaxis with Tixagevimab and Cilgavimab (Evusheld©) for COVID-19 among 1112 Severely Immunocompromised Patients](https://doi.org/10.1016/j.cmi.2022.07.015)’. _Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases_, 1 August 2022, S1198-743X(22)00383-4.
* Ocon, Anthony J., and S. Shahzad Mustafa. ‘[Real-World Experience of Tixagevimab and Cilgavimab (Evusheld) in Rheumatologic Patients on Rituximab](https://doi.org/10.1097/RHU.0000000000001907)’. JCR: Journal of Clinical Rheumatology, 20 September 2022.
* Odriozola Herrán, Aitor, José Ignacio Fortea Ormaechea, Antonio Cuadrado, Ángela Puente Sánchez, Jeffrey V. Lazarus, Javier Crespo, and Emilio Fábrega. ‘[Protective Measures against Omicron Could Be More Effective than Evusheld® in Liver Transplant Recipients](https://doi.org/10.17235/reed.2022.9058/2022)’. _Revista Espanola De Enfermedades Digestivas: Organo Oficial De La Sociedad Espanola De Patologia Digestiva_ 114, no. 12 (December 2022): 769–70.
* Pawankar, Ruby, Bernard Yu-Hor Thong, Marysia Tiongco-Recto, Jiu-Yao Wang, Amir Hamzah Abdul Latiff, Ting Fan Leung, Philip Hei Li, et al. ‘[Asia Pacific Perspectives on the Second Year of the COVID-19 Pandemic: A Follow-up Survey](https://doi.org/10.1111/cea.14191)’. _Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology_ 52, no. 8 (August 2022): 965–73.
* Piszczek, Jolanta, Srinivas Murthy, and Kevin Afra. ‘[Cardiac and Vascular Serious Adverse Events Following Tixagevimab–Cilgavimab](https://doi.org/10.1016/S2213-2600(22)00452-0)’. _The Lancet Respiratory Medicine_, 12 December 2022.
* [PREPRINT] Planas, Delphine, Timothee Bruel, Isabelle Staropoli, Florence Guivel-Benhassine, Francoise Porrot, Piet Maes, Ludivine Grzelak, et al. ‘[Resistance of Omicron Subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to Neutralizing Antibodies](https://doi.org/10.1101/2022.11.17.516888)’. _BioRxiv: The Preprint Server for Biology_, 21 November 2022, 2022.11.17.516888.
* Shaikh, Suhail A., Faiza Morado, Pnada Kawewat-Ho, Rachel Cartus, Roland Davoudi, Kevin Forrester, Krist Azizian, Emily Blodget, Thin Thin Maw, and Neha Nanda. ‘[Tixagevimab-Cilgavimab: Utilization in the Solid Organ Transplant Population](https://doi.org/10.1111/ctr.14661)’. _Clinical Transplantation_ 36, no. 6 (June 2022): e14661.
* Shields, Adrian M, Ariharan Anantharachagan, Gururaj Arumugakani, Kenneth Baker, Sameer Bahal, Helen Baxendale, William Bermingham, et al. 2022. ‘[Outcomes Following SARS-CoV-2 Infection in Patients with Primary and Secondary Immunodeficiency in the UK](https://doi.org/10.1093/cei/uxac008)’. _Clinical and Experimental Immunology_, January, uxac008.
* Singson, Jason Robert C., Pam Daily Kirley, Huong Pham, Gretchen Rothrock, Isaac Armistead, James Meek, Evan J. Anderson, et al. ‘[Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 - COVID-NET, 10 States, March 2020-February 2022](https://doi.org/10.15585/mmwr.mm7127a3)’. MMWR. Morbidity and Mortality Weekly Report 71, no. 27 (8 July 2022): 878–84.
* Stuver, Robert, Gunjan L. Shah, Neha S. Korde, Lindsey E. Roeker, Anthony R. Mato, Connie L. Batlevi, David J. Chung, et al. 2022. ‘[Activity of AZD7442 (Tixagevimab-Cilgavimab) against Omicron SARS-CoV-2 in Patients with Hematologic Malignancies](https://doi.org/10.1016/j.ccell.2022.05.007)’. _Cancer Cell_, May.
* Montgomery, Hugh, F. D. Richard Hobbs, Francisco Padilla, Douglas Arbetter, Alison Templeton, Seth Seegobin, Kenneth Kim, et al. 2022. ‘[Efficacy and Safety of Intramuscular Administration of Tixagevimab–Cilgavimab for Early Outpatient Treatment of COVID-19 (TACKLE): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial](https://doi.org/10.1016/S2213-2600(22)00180-1)’. _The Lancet Respiratory Medicine_.
* Tada, Takuya, Hao Zhou, Belinda M. Dcosta, Marie I. Samanovic, Vidya Chivukula, Ramin S. Herati, Stevan R. Hubbard, Mark J. Mulligan, and Nathaniel R. Landau. ‘[Increased Resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies](https://doi.org/10.1016/j.ebiom.2022.103944)’. _EBioMedicine_ 78 (April 2022): 103944.
* Takashita, Emi, Seiya Yamayoshi, Viviana Simon, Harm van Bakel, Emilia M. Sordillo, Andrew Pekosz, Shuetsu Fukushi, et al. ‘[Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants](https://doi.org/10.1056/NEJMc2207519)’. _New England Journal of Medicine_, 20 July 2022.
* Touret, Franck, Cécile Baronti, Hawa Sophia Bouzidi, and Xavier de Lamballerie. ‘[In Vitro Evaluation of Therapeutic Antibodies against a SARS-CoV-2 Omicron B.1.1.529 Isolate](https://doi.org/10.1038/s41598-022-08559-5)’. _Scientific Reports_ 12, no. 1 (18 March 2022): 4683.
* Touret, Franck, Cécile Baronti, Boris Pastorino, Paola Mariela Saba Villarroel, Laetitia Ninove, Antoine Nougairède, and Xavier de Lamballerie. ‘[In Vitro Activity of Therapeutic Antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5](https://doi.org/10.1038/s41598-022-16964-z)’. _Scientific Reports_ 12, no. 1 (23 July 2022): 12609.
* [PREPRINT] Tuekprakhon, Aekkachai, Jiandong Huo, Rungtiwa Nutalai, Aiste Dijokaite-Guraliuc, Daming Zhou, Helen M. Ginn, Muneeswaran Selvaraj, et al. 2022. ‘[Further Antibody Escape by Omicron BA.4 and BA.5 from Vaccine and BA.1 Serum](https://doi.org/10.1101/2022.05.21.492554)’. _bioRxiv_.
* Whelan, Mary Grace, Leah Santacroce, Lucy Masto, Grace Qian, Emily Kowalski, Kathleen Vanni, Sanjat Kanjilal, Michael E. Weinblatt, Jeffrey A. Sparks, and Sara K. Tedeschi. ‘[Predictors of Low Spike Antibody Response in Patients with Systemic Rheumatic Disease after an Initial Course of COVID-19 Vaccination](https://doi.org/10.1007/s10067-023-06512-z)’. _Clinical Rheumatology_, 19 January 2023, 1–6.
* Willicombe, Michelle, Miranda Scanlon, Fiona Loud, and Liz Lightstone. 2022. ‘[Should We Be Clinically Assessing Antibody Responses to Covid Vaccines in Immunocompromised People?](https://doi.org/10.1136/bmj.o966)’ _BMJ_ 377 (April): o966.
* Wise, Jacqui. ‘[Covid-19: Evusheld Is Approved in UK for Prophylaxis in Immunocompromised People](https://doi.org/10.1136/bmj.o722)’. _BMJ (Clinical Research Ed.)_ 376 (17 March 2022): o722.
* Wu, Mary Y., Edward J. Carr, Ruth Harvey, Harriet V. Mears, Svend Kjaer, Hermaleigh Townsley, Agnieszka Hobbs, et al. ‘[WHO’s Therapeutics and COVID-19 Living Guideline on MAbs Needs to Be Reassessed](https://doi.org/10.1016/S0140-6736(22)01938-9)’. _The Lancet_ (6 October 2022).
* [PREPRINT] Yamasoba, Daichi, Izumi Kimura, Yusuke Kosugi, Keiya Uriu, Shigeru Fujita, Jumpei Ito, Kei Sato, and The Genotype to Phenotype Japan (G2P-Japan) Consortium. ‘[Neutralization Sensitivity of Omicron BA.2.75 to Therapeutic Monoclonal Antibodies](https://doi.org/10.1101/2022.07.14.500041)’. _bioRxiv_, 15 July 2022.
* Yamasoba, Daichi, Yusuke Kosugi, Izumi Kimura, Shigeru Fujita, Keiya Uriu, Jumpei Ito, and Kei Sato. 2022. ‘[Neutralisation Sensitivity of SARS-CoV-2 Omicron Subvariants to Therapeutic Monoclonal Antibodies](https://doi.org/10.1016/S1473-3099(22)00365-6)’. _The Lancet Infectious Diseases_.
* [PREPRINT] Young-Xu, Yinong, Lauren Epstein, Vincent C. Marconi, Victoria Davey, Gabrielle Zwain, Jeremy Smith, Caroline Korves, Fran Cunningham, Robert Bonomo, and Adit A. Ginde. 2022. ‘[Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic Data](https://doi.org/10.1101/2022.05.28.22275716)’. _medRxiv_.

## Secondary References
This secondary bibliography presents a selection of references on topics not directly related to Evusheld but that are of interest (e.g. the mental health implications of shielding).

* Daniels, Jo, and Hannah Rettie. ‘[The Mental Health Impact of the COVID-19 Pandemic Second Wave on Shielders and Their Family Members](https://doi.org/10.3390/ijerph19127333)’. International Journal of Environmental Research and Public Health 19, no. 12 (January 2022): 7333.

## Events
* AstraZeneca. 2022. ‘[The Unmet Needs of Immunocompromised Patients Post-COVID 19](https://www.politico.eu/event/the-unmet-needs-of-immunocompromised-patients-post-covid-19/)’. _POLITICO_. 9 June 2022.

## Media

<iframe src="https://player.vimeo.com/video/719537557?h=78adcb4cb9" width="640" height="480" frameborder="0" allow="autoplay; fullscreen; picture-in-picture" allowfullscreen></iframe>
<p><a href="https://vimeo.com/719537557">BBC News - 3pm - 21 February 2022</a> from <a href="https://vimeo.com/shannonleebanks">Shannon Banks</a> on <a href="https://vimeo.com">Vimeo</a>.</p>


<iframe width="560" height="315" src="https://www.youtube.com/embed/Xstee16fIPE" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>


<iframe src="https://player.vimeo.com/video/733719996?h=0be83c25e6" width="640" height="480" frameborder="0" allow="autoplay; fullscreen; picture-in-picture" allowfullscreen></iframe>
<p><a href="https://vimeo.com/733719996">Channel 5 News - 5pm - 12 July 2022</a> from <a href="https://vimeo.com/shannonleebanks">Shannon Banks</a> on <a href="https://vimeo.com">Vimeo</a>.</p>


<iframe src="https://player.vimeo.com/video/733719643?h=2563d6c38b" width="640" height="480" frameborder="0" allow="autoplay; fullscreen; picture-in-picture" allowfullscreen></iframe>
<p><a href="https://vimeo.com/733719643">ITV News - 6:30pm - 26 July</a> from <a href="https://vimeo.com/shannonleebanks">Shannon Banks</a> on <a href="https://vimeo.com">Vimeo</a>.</p>